Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.

Jakhar, Deepak; Kaur, Ishmeet

Jakhar, Deepak; Kaur, Ishmeet.

Jakhar D; Department of Dermatology, North Delhi Municipal Corporation Medical College and Hindu Rao Hospital, New Delhi, India. dr.deepakjakhar@yahoo.in.
Kaur I; Department of Dermatology, North Delhi Municipal Corporation Medical College and Hindu Rao Hospital, New Delhi, India.

Nat Med ; 26(5): 632, 2020 05.

Article in English | MEDLINE | ID: covidwho-47143

Subject(s)

Betacoronavirus; Chloroquine/therapeutic use; Coronavirus Infections/drug therapy; Hydroxychloroquine/therapeutic use; Lupus Erythematosus, Systemic; Pneumonia, Viral/drug therapy; COVID-19; Chloroquine/supply & distribution; Fear; Humans; Hydroxychloroquine/supply & distribution; Lupus Erythematosus, Systemic/drug therapy; Pandemics; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Chloroquine / Coronavirus Infections / Betacoronavirus / Hydroxychloroquine / Lupus Erythematosus, Systemic Limits: Humans Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2020 Document Type: Article Affiliation country: S41591-020-0853-0

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google